Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.

Gaucher disease causes pathologic skeletal changes that are not fully explained. Considering the important role of mesenchymal stromal cells (MSCs) in bone structural development and maintenance, we analyzed the cellular biochemistry of MSCs from an adult patient with Gaucher disease type 1 (N370S/L444P mutations). Gaucher MSCs possessed a low glucocerebrosidase activity and consequently had a 3-fold increase in cellular glucosylceramide. Gaucher MSCs have a typical MSC marker phenotype, normal osteocytic and adipocytic differentiation, growth, exogenous lactosylceramide trafficking, cholesterol content, lysosomal morphology, and total lysosomal content, and a marked increase in COX-2, prostaglandin E2, interleukin-8, and CCL2 production compared with normal controls. Transcriptome analysis on normal MSCs treated with the glucocerebrosidase inhibitor conduritol B epoxide showed an up-regulation of an array of inflammatory mediators, including CCL2, and other differentially regulated pathways. These cells also showed a decrease in sphingosine-1-phosphate. In conclusion, Gaucher disease MSCs display an altered secretome that could contribute to skeletal disease and immune disease manifestations in a manner distinct and additive to Gaucher macrophages themselves.

[1]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[2]  A. Galione,et al.  Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium , 2008, Nature Medicine.

[3]  M. V. van Breemen,et al.  Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[4]  J. Hopwood,et al.  Lipid composition of microdomains is altered in a cell model of Gaucher disease** This work was supported by a National Health and Medical Research Council project grant in Australia. Published, JLR Papers in Press, April 21, 2008. , 2008, Journal of Lipid Research.

[5]  R. Proia,et al.  Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. , 2008, Human molecular genetics.

[6]  Ying Sun,et al.  Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient mice , 2008, BMC Neuroscience.

[7]  Joel S Greenberger,et al.  Age‐related intrinsic changes in human bone‐marrow‐derived mesenchymal stem cells and their differentiation to osteoblasts , 2008, Aging cell.

[8]  U. Galderisi,et al.  A case report: Bone marrow mesenchymal stem cells from a rett syndrome patient are prone to senescence and show a lower degree of apoptosis , 2008, Journal of cellular biochemistry.

[9]  P. Meikle,et al.  Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease. , 2008, Molecular genetics and metabolism.

[10]  C. Hollak,et al.  Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature , 2008, Annals of Hematology.

[11]  M. Harada,et al.  Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease , 2007, Pediatrics international : official journal of the Japan Pediatric Society.

[12]  P. Meikle,et al.  Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. , 2007, Molecular genetics and metabolism.

[13]  L. Qin,et al.  Parathyroid Hormone Stimulates Osteoblastic Expression of MCP-1 to Recruit and Increase the Fusion of Pre/Osteoclasts* , 2007, Journal of Biological Chemistry.

[14]  U. Lerner,et al.  Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[15]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[16]  C. Hollak,et al.  Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type 1 Gaucher disease , 2007 .

[17]  G. Tell,et al.  Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress , 2007, Journal of cellular physiology.

[18]  A. McIntosh,et al.  Sterol carrier protein-2: new roles in regulating lipid rafts and signaling. , 2007, Biochimica et biophysica acta.

[19]  R. Pagano,et al.  Using Fluorescent Sphingolipid Analogs to Study Intracellular Lipid Trafficking , 2007, Current protocols in cell biology.

[20]  S. Gummadi,et al.  Phospholipid scramblases: an overview. , 2007, Archives of biochemistry and biophysics.

[21]  J. Martignetti,et al.  Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. , 2007, Human molecular genetics.

[22]  A. Mehta,et al.  Enhanced differentiation of osteoclasts from circulating mononuclear precursors in patients with Gaucher disease , 2007 .

[23]  J. Galipeau,et al.  Immune plasticity of bone marrow-derived mesenchymal stromal cells. , 2007, Handbook of experimental pharmacology.

[24]  M. V. van Breemen,et al.  Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. , 2007, Biochimica et biophysica acta.

[25]  David S. Wishart,et al.  The Online Metabolic and Molecular Bases of Inherited Disease; Chapter 3.1: Metabolism and Metabolic Disease Resources on the Web, Page 1 , 2007 .

[26]  A. Futerman.  Cellular Pathology in Gaucher Disease , 2006 .

[27]  A. Lucci,et al.  Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. , 2006, The Journal of surgical research.

[28]  J. Galipeau,et al.  Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. , 2006, Journal of the American Society of Nephrology : JASN.

[29]  J. Fletcher.  Screening for lysosomal storage disorders—A clinical perspective , 2006, Journal of Inherited Metabolic Disease.

[30]  J. Galipeau,et al.  Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. , 2006, Blood.

[31]  C. Selinger,et al.  MCP-1-induced Human Osteoclast-like Cells Are Tartrate-resistant Acid Phosphatase, NFATc1, and Calcitonin Receptor-positive but Require Receptor Activator of NFκB Ligand for Bone Resorption* , 2006, Journal of Biological Chemistry.

[32]  D. Ribatti,et al.  Bone marrow endothelial cells in multiple myeloma secrete CXC‐chemokines that mediate interactions with plasma cells , 2005, British journal of haematology.

[33]  P. Meere,et al.  Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I) , 2005, Current opinion in rheumatology.

[34]  L. Boon,et al.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. , 2004, American journal of clinical pathology.

[35]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[36]  L. Suva,et al.  Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. , 2003, Bone.

[37]  T. Cox.  Future perspectives for glycolipid research in medicine. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[38]  Sarah Spiegel,et al.  Sphingosine-1-phosphate: an enigmatic signalling lipid , 2003, Nature Reviews Molecular Cell Biology.

[39]  K. Vanderkerken,et al.  Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3 , 2003, British Journal of Cancer.

[40]  R. Dwek,et al.  Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.

[41]  Kenneth Dixon,et al.  Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. , 2002, Arthritis and rheumatism.

[42]  T. Sugihara,et al.  IL-10 in Myeloma Cells , 2002, Leukemia & lymphoma.

[43]  D. Phinney.  Building a consensus regarding the nature and origin of mesenchymal stem cells , 2002, Journal of cellular biochemistry. Supplement.

[44]  K. Simons,et al.  Jamming the endosomal system: lipid rafts and lysosomal storage diseases. , 2000, Trends in cell biology.

[45]  E. Young,et al.  Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. , 2000, Blood.

[46]  R. Desnick,et al.  Gaucher disease: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patients , 2000, European Journal of Human Genetics.

[47]  M. Patterson,et al.  Broad screening test for sphingolipid-storage diseases , 1999, The Lancet.

[48]  V. Barak,et al.  Cytokines in Gaucher's disease. , 1999, European cytokine network.

[49]  C. Martínez-A,et al.  Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. , 1997, Journal of immunology.

[50]  M. Horowitz,et al.  Expression of mutated glucocerebrosidase alleles in human cells. , 1997, Human molecular genetics.

[51]  Sheila J. Jones,et al.  Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. , 1996, Development.

[52]  B. Rollins.  JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. , 1991, Cancer cells.

[53]  H. Radzun,et al.  Tartrate-resistant, purple acid phosphatase in Gaucher cells of the spleen. Immuno- and cytochemical analysis. , 1991, Pathology, research and practice.

[54]  F. Hommes.  Techniques in diagnostic human biochemical genetics : a laboratory manual , 1991 .

[55]  J. Kanfer,et al.  The Gaucher mouse. , 1982, Progress in clinical and biological research.

[56]  M. Adachi,et al.  Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features. , 1977, Archives of pathology & laboratory medicine.